Management of urogenital gonococcal infection
Drug and Therapeutics Bulletin · 03.08.2026 · dtb-2025-000038
DOI: 10.1136/dtb.2025.000038 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 03.08.2026. Verfasst von Soonita Oomeer. Beteiligte Einrichtung: Genitourinary Medicine, Central and North West London NHS Foundation Trust, London, UK soonita.oomeer@nhs.net. Die Arbeit nennt 53 Literaturangaben.
Abstract (Originalsprache)
Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae , is the second most common bacterial sexually transmitted infection diagnosed in the UK. Diagnoses remain highest among specific population groups: men who have sex with men, young people aged 15–24 years, and individuals of black Caribbean and mixed ethnicities. While most infections are asymptomatic, gonococcal infection can cause painful urogenital symptoms and, left untreated, can result in complications including pelvic inflammatory disease, epididymo-orchitis and infertility. Although infections can be treated successfully, there has been a concerning rise in diagnoses of antibiotic-resistant gonorrhoea in recent times. Treatment options are limited due to antimicrobial resistance and a lack of newer treatment options available. Sexual contacts should be treated if they test positive. Ceftriaxone remains a safe, effective first-line treatment. Ceftriaxone-resistant cases are being detected more frequently although numbers remain low in England and Wales. The recent roll-out of the world’s first vaccination programme to protect against gonorrhoea infection is anticipated to save the NHS millions of pounds over the next decade. It remains to be seen whether this measure will effectively curb escalating national infection rates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genitourinary Medicine, Central and North West London NHS Foundation Trust, London, UK soonita.oomeer@nhs.net.
Zitieren
APA
Oomeer, S. (2026). Management of urogenital gonococcal infection. Drug and Therapeutics Bulletin, dtb-2025-000038. https://doi.org/10.1136/dtb.2025.000038
Vancouver
Oomeer S. Management of urogenital gonococcal infection. Drug and Therapeutics Bulletin. 2026:dtb-2025-000038. doi:10.1136/dtb.2025.000038
BibTeX
@article{Oomeer2026,
author = {Oomeer, Soonita},
title = {Management of urogenital gonococcal infection},
journal = {Drug and Therapeutics Bulletin},
year = {2026},
pages = {dtb--2025--000038},
doi = {10.1136/dtb.2025.000038}
}
EUVIMED